Pfizer’s CTI and ADDF to co-fund new project to treat neurodegenerative diseases


The Alzheimer’s Drug Discovery Foundation (ADDF) and Pfizer’s Centers for Therapeutic Innovation (CTI) will jointly fund a new project that seeks to develop potential treatments for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases.

Created by Pfizer, CTI is a model designed for academic-foundation-industry collaboration that would help bridge the gap between early scientific discovery and its translation into new medicines.

The project is being led by Dr Valina Dawson of the Department of Neurology and a team of researchers at Johns Hopkins University School of Medicine.

The current collaboration is particularly significant in Alzheimer’s disease, which currently has no available disease-modifying treatment options.

"The goal of this collaboration with the ADDF is to find the most promising new targets for treating Alzheimer’s and Parkinson’s."

Pfizer External Science and Innovation Group senior vice-president Dr Uwe Schoenbeck said: “By combining Dr Dawson’s approach and expertise with Pfizer’s drug development expertise and resources, we hope to accelerate and optimise the development of a potential therapy to patients.

“The goal of this collaboration with the ADDF is to find the most promising new targets for treating Alzheimer’s and Parkinson’s and develop potential medicines against them as quickly as possible to the benefit of patients.”

Besides receiving funding from CTI and the ADDF, the project team will also benefit from the drug development expertise and resources of Pfizer’s CTI, as well as the disease knowledge of the ADDF.

During the project, Dr Dawson will work in collaboration with Pfizer’s CTI director Dr Paul Wes and scientists from the company’s Neuroscience, Medicinal Chemistry, Primary Pharmacology, and Drug, Safety, Research and Development units.